StreetAlpha
13F holdings · Q3 2026

Opaleye Management

Boston, MA · files as Opaleye Management Inc.
Know the moment Opaleye Management filesYou follow Opaleye Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1595855

Opaleye Management reported 58 stocks worth $888M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ETON (14.2%), IRON (8.1%) and HROW (7.3%). Compared with Q2 2026, the fund opened new positions in SMMT, HRMY and GRCE, added to IRON, SLGL and MGTX, trimmed ETON, HROW and LQDA and sold out of NTLA, PHAT and COAG.

Latest filing: what Opaleye Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
10 new17 added19 trimmed10 sold outBought about $130M · sold about $178M
New 10
See all 10 →
Added 17
See all 17 →
Trimmed 19
See all 19 →
Sold out 10
  • Apogee Therapeutic$51.8M
  • Xoma Royalty Corpo$14.4M
  • NTLA$4.2M
  • PHAT$2M
  • COAG$1.8M
See all 10 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$888M−19.6% vs last quarter
Stocks held5810 new · 10 sold out
Top 5 weight43.3%fairly concentrated
Turnover35%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
ETON
Eton Pharmaceuticals Inc
$126M14.2%2.4M−420K (−15%)8 of 8
2
IRON
Disc Medicine Inc
$71.7M8.1%1.1M+240K (+28%)7 of 8
3
HROW
Harrow Inc
$64.8M7.3%2.1M−295K (−12%)8 of 8
4
LQDA
Liquidia Corporation
$63.8M7.2%2.1M−338K (−14%)8 of 8
5
URGN
Urogen Pharma Ltd
$58.5M6.6%1.4MNo change5 of 8
6
SLGL
Sol Gel Technologies
$41.2M4.6%555K+55K (+11%)5 of 8
7
MGTX
Meiragtx Hldgs PLC
$39.6M4.5%3.6M+50K (+1%)4 of 8
8
TGTX
TG Therapeutics Inc
$31.1M3.5%557K+22K (+4%)8 of 8
9
ACOG
Alpha Cognition Inc
$29.7M3.4%3.3M+408K (+14%)5 of 8
10
IMMX
Immix Biopharma Inc
$29.4M3.3%2.8M+480K (+20%)2 of 8
🔒 48 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
APOGEE THERAPEUTICS INC
$51.8M390K
XOMA ROYALTY CORPORATION
$14.4M338K
NTLA
Intellia Therapeutics Inc
$4.2M250K
PHAT
Phathom Pharmaceuticals Inc
$2M186K
COAG
Hemab Therapeutics Hldgs Inc
$1.8M48K

🔒 Free account: see all 10.

Reported value

last 8 quarters
$561MQ4 '24
$438MQ1 '25
$484MQ2 '25
$703MQ3 '25
$758MQ4 '25
$759MQ1 '26
$1.1BQ2 '26
$888MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Opaleye Management 13F FAQ

What does Opaleye Management own?

Opaleye Management reported 58 stocks worth $888M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ETON (14.2%), IRON (8.1%) and HROW (7.3%). The table above lists every position in the filing (the top 10 without an account).

What did Opaleye Management buy and sell in Q3 2026?

Compared with Q2 2026: 10 new positions, 17 added to, 19 trimmed and 10 sold out. New positions include SMMT, HRMY and GRCE. It sold all of NTLA, PHAT and COAG.

When will Opaleye Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Opaleye Management's portfolio worth?

The Q3 2026 filing reports $888M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.